Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...

(UroToday.com) The 2022 American Urological Association Annual Meeting included a prostate cancer session featuring work from Dr. Mohammad Siddiqui and colleagues presenting results of their study ...

(UroToday.com) In this presentation, Dr. Michael Morris presented the results of the phase 3 VISION trial evaluating the radiopharmaceutical lutetium-PSMA (Lu-PSMA) in patients with metastatic ...

(UroToday.com) The 2023 American Urological Association (AUA) annual meeting held in Chicago, IL between April 28 and May 1st, 2023, was host to the Arab Association of Urology sectional session. Dr.

(UroToday.com) The 2023 European Society of Medical Oncology (ESMO) Annual Congress held in Madrid, Spain between October 20 th and 24 th, 2023 was host to a non-prostate genitourinary proffered paper ...

(Urotoday.com) The newly formed Global Society of Rare Genitourinary Tumors (GSRGT) held its inaugural meeting, focusing on penile and testicular cancer. The session held Saturday, December 12 th ...

EAU 2024 trial design of SunRISe-3, TAR-200 plus cetrelimab or TAR-200 versus intravesical BCG, BCG-naive high-risk non–muscle-invasive bladder cancer, transure ...

(UroToday.com) The 2024 American Society of Clinical Oncology (ASCO) annual meeting featured a session on prostate cancer, and a presentation by Dr. Daniel Petrylak discussing initial results of a ...

Wallace BK, Su ZT, Flynn JP, Garman TS, Weitzner A, Rezaee ME, et al. National trends in diagnoses of subtype histologies in bladder cancer: A population-based study based on the SEER database. Urol ...

Patients with bone-protecting agent use versus no bone-protecting agent had similar baseline characteristics: ...

The PI3K/AKT/mTOR signaling pathway plays a critical role in regulating cellular growth, survival, metabolism, and proliferation. In prostate cancer, especially in advanced stages, this pathway ...

Daniel George presents the CAPItello-281 study examining capivasertib combined with abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer. The study screened over 6,000 patients ...